After back-to-back trial flops, Realm slashes its staff, halts research work and ponders a fire sale
Just days after reporting its second mid-stage trial failure in 5 months, little Realm Therapeutics $RLM is throwing in the towel.
The Phase II failure in atopic dermatitis — a crowded field which includes some notable giants — came on the heels of scrapping its Phase II program for PR013, a topical ophthalmic solution for the treatment of allergic conjunctivitis.
It was all too much for the investors at the Malvern, PA biotech to swallow. Monday morning the biotech put out the word that it is abandoning all clinical trial work and putting itself up for sale, slashing its staff roster in the process.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.